EBV‐CTLs targeting type II latency antigens (e.g., EBNA1, LMP1, LMP2) show promise for nasopharyngeal carcinoma (NPC) and lymphomas. This evidence concerns the gene PSMB9 and nasopharyngeal carcinoma.